Martingale Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Martingale Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-38,629	Closed	-$1.48M	–	864
2023 Q2	$1.48M	Sell	38,629 -6,909	-15%	-$177K	0.03%	343
2023 Q1	$1.05M	Buy	45,538 +5	+0%	+$119	0.02%	430
2022 Q4	$1.19M	Buy	45,533 +206	+0.5%	+$4.56K	0.02%	407
2022 Q3	$892K	Buy	45,327 +4,110	+10%	+$82.4K	0.02%	474
2022 Q2	$721K	Buy	41,217 +1,300	+3%	+$20.4K	0.01%	556
2022 Q1	$654K	Buy	39,917 +11,902	+42%	+$162K	0.01%	580
2021 Q4	$457K	Buy	28,015 +15,200	+119%	+$216K	0.01%	664
2021 Q3	$164K	Buy	+12,815	New	+$169K	﹤0.01%	831

Martingale Asset Management's KDNY Position: Q3 2023 in Review

Martingale Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 38,629 shares — an estimated $1.48M sold.

Martingale Asset Management first reported a position in KDNY in Q3 2021 and held it in 8 quarters. The position peaked at $1.48M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Martingale Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Martingale Asset Management sold 38,629 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.48M.
Martingale Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Martingale Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.48M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Martingale Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.